Zynex Inc. (OTCMKTS:ZYXI) CFO Purchases $49,494.63 in Stock
Zynex Inc. (OTCMKTS:ZYXI) CFO Daniel J. Moorhead bought 2,733 shares of Zynex stock in a transaction on Thursday, July 30th. The shares were purchased at an average price of $18.11 per share, for a total transaction of $49,494.63. Following the acquisition, the chief financial officer now directly owns 19,001 shares in the company, valued at approximately $344,108.11. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
ZYXI stock opened at $19.12 on Friday. The stock has a market capitalization of $663.58 million, a PE ratio of 86.91 and a beta of 1.05. Zynex Inc. has a 12-month low of $7.51 and a 12-month high of $29.73. The stock’s 50 day simple moving average is $23.36 and its 200 day simple moving average is $16.05.
Zynex (OTCMKTS:ZYXI) last released its quarterly earnings data on Tuesday, July 28th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. The business had revenue of $19.26 million for the quarter, compared to analysts’ expectations of $19.12 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. As a group, analysts predict that Zynex Inc. will post 0.28 EPS for the current year.
Institutional investors have recently modified their holdings of the company. Citigroup Inc. grew its position in shares of Zynex by 310.6% during the fourth quarter. Citigroup Inc. now owns 3,170 shares of the company’s stock valued at $25,000 after purchasing an additional 2,398 shares in the last quarter. Winslow Evans & Crocker Inc. purchased a new position in shares of Zynex during the second quarter valued at about $107,000. Strs Ohio grew its position in shares of Zynex by 84.6% during the second quarter. Strs Ohio now owns 4,800 shares of the company’s stock valued at $119,000 after purchasing an additional 2,200 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Zynex by 121.9% during the first quarter. BNP Paribas Arbitrage SA now owns 4,866 shares of the company’s stock valued at $54,000 after purchasing an additional 2,673 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund purchased a new position in shares of Zynex during the second quarter valued at about $152,000. Hedge funds and other institutional investors own 0.05% of the company’s stock.
Zynex Company Profile
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Featured Story: High-Yield Dividend Stocks
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.